LONDON : A phase one trial of a multivariant COVID-19 vaccine booster drug has got underway among participants aged over 60 in the UK.
The trial, involving GRT-R910, has been launched by US pharmaceutical company Gritstone in collaboration with the University of Manchester and Manchester University NHS Foundation Trust.
It will explore the potential of the drug to boost the immune response of first-generation COVID-19 vaccines to a wide array of variants of Sars-Cov-2, which cause COVID-19. “We think GRT-R910 as a booster vaccination will elicit strong, durable, and broad immune responses, which are likely to be critical in maintaining protection of this vulnerable elderly population who are particularly at risk of hospitalisation and